marketinference

Recursion Pharmaceuticals and Exscientia PLC Shareholders Approve Merger

Recursion (NASDAQ: RXRX) and Exscientia PLC (NASDAQ: EXAI) have announced that their shareholders have overwhelmingly approved the proposed combination between the two companies. The transaction is ...

What is Model Collapse in AI? Causes, Signs, Consequences and Prevention

Discover what AI model collapse is, its causes, early warning signs, and severe consequences. Learn how to prevent recursive ...

Notable Researchers Join $4 Billion Effort to Build Self-Improving A.I.

Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate ...
The New York Times

Silicon Valley Wants to Build A.I. That Can Improve A.I. on Its Own

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...
GEN

Recursion’s Incoming CEO on Turning AI Drugs Into Clinical Proof Points

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
The Motley Fool

3 Things Investors Need to Know About Recursion Pharmaceuticals

Recursion Pharmaceuticals uses AI to develop drugs. The company's goal is to improve and speed up a process that is slow, expensive, and risky. Most medicines that enter the clinic never make it to ...
Seeking Alpha

Recursion Pharmaceuticals: Recent Gains Are Mysterious Given A Lack Of Overall Progress

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
Frontiers

Visual recursion without recursive language? a case study of a minimally verbal autistic child

The human faculty to generate an infinite set of structured expressions in language, present in most cultures and normal ontogeny, is the most substantial evidence of the human capacity for recursion.
Nasdaq

MIT and Recursion Unveil Boltz-2: A Revolutionary Open-Source Biomolecular Co-Folding Model with Advanced Structure and Binding Affinity Prediction

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. MIT and Recursion have released Boltz-2, the first ...
JD Supra

Recursive Artificial Intelligence: Can the Law Keep Up?

While Artificial Intelligence (AI) has emerged as groundbreaking and significantly impacting various sectors and enhancing quality of life, the chasm between technological advancements and the law is ...
The Motley Fool

4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today

Recursion stands out as a pure play in AI-powered biotech, using machine learning algorithms to accelerate drug research and development (R&D). The company's BioHive-2 supercomputer, powered by Nvidia ...